Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide

• DOI: 10.1038/s41408-024-01039-1
• Publication Date: 2024-03-26T12:02:48Z
• Authors: Utkarsh Goel; Charalampos Chara...; Prashant Kapoor; Moritz Binder; Francis K. Buadi; David Dingli; Angela Dispenzieri; Amie Fonder; Morie A. Gertz; Wilson I. Gonsalves; Suzanne R. Hayman; Miriam A. Hobbs; Yi L. Hwa; Taxiarchis Kourelis; Martha Q. Lacy; Nelson Leung; Yi Lin; Rahma M. Warsame; Robert A. Kyle; S. Vincent Rajkumar; Shaji K. Kumar
• Keywords: Refractory (planetary science)

Abstract Refractoriness to lenalidomide is an important factor determining the choice of therapy at first relapse in multiple myeloma (MM). It remains debatable if resistance varies among MM refractory standard doses vs low dose maintenance doses. In this study, we assessed outcomes with subsequent therapies patients lenalidomide. We retrospectively reviewed all our institution who received line containing regimens, and progression free survival (PFS) overall for these second therapy, retreatment. For found no difference PFS between groups (median 14 months months, p = 0.95), while both was inferior not group 30 < 0.001 pairs). Similar trends were seen on retreatment, multivariable analysis. These data suggest that refractoriness dependent, definition should depend which disease considered refractory.